DURECT (NASDAQ:DRRX – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, March 26th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $6.91 million for the quarter.
DURECT Price Performance
NASDAQ:DRRX opened at $0.80 on Wednesday. The business has a fifty day simple moving average of $0.80 and a two-hundred day simple moving average of $1.04. DURECT has a 1 year low of $0.70 and a 1 year high of $1.88. The company has a market capitalization of $24.83 million, a P/E ratio of -1.31 and a beta of 0.91.
Wall Street Analysts Forecast Growth
Separately, StockNews.com started coverage on DURECT in a research report on Wednesday. They issued a “sell” rating for the company.
About DURECT
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
Featured Stories
- Five stocks we like better than DURECT
- How to Use Stock Screeners to Find Stocks
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- 3 Must-Own Stocks to Build Wealth This Decade
- Buy P&G Now, Before It Sets A New All-Time High
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.
